Meeder Asset Management Inc. lifted its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 110,664 shares of the company’s stock after buying an additional 974 shares during the quarter. Johnson & Johnson makes up 1.0% of Meeder Asset Management Inc.’s holdings, making the stock its 14th largest holding. Meeder Asset Management Inc.’s holdings in Johnson & Johnson were worth $14,317,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Phocas Financial Corp. boosted its position in Johnson & Johnson by 999,928.6% during the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock valued at $1,743,000 after purchasing an additional 125,161,066 shares in the last quarter. Nuveen Asset Management LLC raised its stake in Johnson & Johnson by 5,447.1% in the second quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock valued at $2,357,266,000 after buying an additional 16,619,550 shares during the last quarter. Thoroughbred Financial Services LLC raised its stake in Johnson & Johnson by 14,147.0% in the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock valued at $401,425,000 after buying an additional 3,986,071 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Johnson & Johnson by 145.5% in the second quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock worth $604,637,000 after purchasing an additional 2,572,695 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Johnson & Johnson by 11.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock worth $2,895,870,000 after purchasing an additional 2,204,757 shares during the last quarter. 72.25% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:JNJ traded up $1.57 during trading on Friday, reaching $133.00. The stock had a trading volume of 4,856,974 shares, compared to its average volume of 7,224,392. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The stock has a market cap of $343.25 billion, a PE ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The business has a fifty day moving average price of $130.83 and a 200-day moving average price of $134.05.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. The company had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.05 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 8.65 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Monday, November 25th. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
Several research firms recently commented on JNJ. Raymond James dropped their target price on Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Credit Suisse Group raised their target price on Johnson & Johnson from $158.00 to $163.00 in a report on Thursday, October 24th. Wells Fargo & Co dropped their target price on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating on the stock in a report on Wednesday, October 16th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $145.00 price objective on shares of Johnson & Johnson in a report on Tuesday, August 27th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $151.64.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: How to trade on quiet period expirations
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.